Cambridge, Mass. and Sydney, Australia
Pi Health, an AI-native contract research organization, has announced a strategic partnership with Filamon Limited, an Australian clinical-stage pharmaceutical company. The collaboration aims to advance clinical development of innovative anti-inflammatory medications targeting age-related chronic inflammatory conditions.
Partnership Focus
The collaboration leverages Pi Health's advanced clinical trial technology to support Filamon's expanding drug development pipeline. The partnership combines Pi Health's technological capabilities with Filamon's expertise in next-generation anti-inflammatory therapeutics.
About the Companies
Pi Health operates as a global AI-driven contract research organization specializing in clinical trial innovation and management.
Filamon Limited is a clinical-stage biotech firm based in Australia dedicated to developing novel anti-inflammatory treatments for conditions associated with aging and chronic inflammation.
Strategic Significance
This partnership represents a convergence of technological innovation and pharmaceutical development expertise, positioning both organizations to accelerate the path from drug discovery to clinical application for patients requiring new anti-inflammatory treatment options.